简介：贝代单抗（bevacizumab）是近几年出现的重组单克隆抗体，通过抑制血管内皮生长因子（VEGF）达到抑制新生血管生成的作用。在眼科中，对于角膜、虹膜、脉络膜、视网膜的新生血管及年龄相关性黄斑变性、黄斑水肿等疾病的治疗具有很可观的应用前景。

简介：瞄准：在先进或变形的颜色加irinotecan+/-bevacizumab调查cape-citabine的功效和安全表面的癌症病人。方法：四十六个病人与以前未经治疗，局部地进展或变形颜色表面的癌症(mCRC)在未来的开标签的阶段II试用在2001-2006之间被招募，在德国基于社区的门诊病人诊所。病人们加bevacizumab(CAPIRI十亿电伏)加irinotecan(CAPIRI)或CAPIRI收到了标准capecitabine政体每3wk。剂量减小从在>等级2毒性的情况下的第一个周期是强制的。bevacizumab的治疗选择依据见解医生。主要端点是反应和毒性，第二等的端点包括了没有前进的幸存和全面幸存。结果：在CAPIRI组对CAPRI十亿电伏组，比男病人(47%对24%)有更多的女性，并且更多的病人与作为主要肿瘤地点(5.9%对20.7%)有S字形的冒号的更少病人一起作为主要肿瘤地点(58.8%对48.2%)有冒号。等级3/4毒性比CAPIRI十亿电伏与CAPIRI是更高的：82%对58.6%。部分反应率是29.4%和34.5%，并且肿瘤控制率分别地是70.6%和75.9%。没有完全的回答被观察。中部的没有前进的幸存分别地为CAPIRI和CAPIRI十亿电伏是11.4瞬间和12.8瞬间。为CAPIRI的中部的全面幸存是15瞬间(458d)并且为CAPIRI十亿电伏24瞬间(733d)。这些差别不是统计上不同的。在CAPIRI十亿电伏，组织，二个病人在治疗以后经历了完整的第二等的肿瘤切除术，而在CAPIRI组没有盒子经历了这个过程。结论：政体很好被容忍并且在这门诊病人设置为有效肿瘤提供了生长控制。严重胃肠的毒性和thromboembolic事件是稀罕的并且如果观察从来不是致命的。

简介：AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.

简介：AIM:Tocomparetherapeuticeffectsofintravitrealtriamcinoloneacetonide(IVTA)versusintravitrealbevacizumab(IVB)injectionsforbilateraldiffusediabeticmacularedema(DDME).METHODS:Fortyeyesof20patientswithbilateralDDMEparticipatedinthisstudy.Foreachpatient,4mg/0.1mLIVTAwasinjectedtooneeyeand2.5mg/0.1mLIVBwasinjectedtotheothereye.Theeffectsofinjectionfordiabeticmacularedema(DME)wereevaluatedusingbest-correctedvisualacuity(BCVA),centralmacularthickness(CMT)byopticalcoherencetomography(OCT)andintraocularpressure(IOP)byapplanationtonometer.Patientsunderwenteyeexaminations,includingBCVA,CMT,andIOPatpre-injection,1,4,8,12and24wkafterinjection.Duringthefollow-up,secondinjectionswereperformedtoeyeswhichhaveCMTgreaterthan400μmat12wkforsalvagetherapy.RESULTS:BCVA(logarithmoftheminimumangleofresolution)atpre-injection,1,4,8,12and24wkafterinjectionwas0.71±0.19,0.62±0.23,0.63±0.12,0.63±0.13,0.63±0.14and0.61±0.24intheIVTAgroupand0.68±0.25,0.61±0.22,0.60±0.24,0.62±0.25,0.65±0.26and0.59±0.25intheIVBgroup,respectively.CMT(μm)atpre-injection,1,4,8,12and24wkafterinjectionwas544±125,383±96,335±87,323±87,333±92,335±61intheIVTAgroupand514±100,431±86,428±107,442±106,478±112,430±88intheIVBgrouprespectively.ReductionratiosofmeanCMTwere29%at1wk,38%at4wk,40%at8wk,38%at12wk,and38%at24wkintheIVTAgroup.SecondIVTAinjectionswereperformedtothe6eyes(30%)at12wk.ReductionratiosofmeanCMTwere16%at1wk,17%at4wk,14%at8wk,7%at12wk,and16%at24wkintheIVBgroup.SecondIVBinjectionswereperformedtothe15eyes(75%)at12wk.CONCLUSION:Thisstudyshowedearlierandmorefrequentmacularedemarecurrencesintheeyestreatedwithbevacizumabcomparedwiththeonestreatedwithtriamcinoloneacetonide.Triamcinoloneacetonidewasfoundtoprovidemoreefficientandlo

简介：诱发角膜新生血管的因素涉及各种生长因子。研究表明：在角膜新生血管中广泛存在的血管内皮生长因子（Vascularendothelialgrowthfactor．VEGF）起着主要作用。一种可行的治疗角膜新生血管策略是：通过特异性的中和抗VEGF抗体竞争性的结合VEGF，从而抑制VEGF活性。近年来，利用抗VEGF治疗策略，抑制脉络膜新生血管获得了很好的效果。靶向VEGF治疗药物的疗效和安全性已经证明。因此我们设想，局部应用新的抗VEGF药物，如贝伐单抗、兰尼单抗等可以有效地抑制角膜新生血管，恢复角膜透明和视力。

简介：·AIM:Toinvestigatethepossibleeffectsofintracameralbevacizumabonoxidativestressparametersandapoptosisincornealtissue.·METHODS:Intotal,30ratswereassignedrandomlyintothefollowingthreegroupsof10ratseach:ashamgroup(Group1;n=10),acontrolgroup[Group2;balancedsaltsolution(BSS)wasadministeredat0.01mL;n=10],andatreatmentgroup(Group3;bevacizumabwasadministeredat0.25mg/0.01mL;n=10).Thetotalantioxidantstatus(TAS)andthetotaloxidantstatus(TOS)inthecornealtissueandbloodsamplesweremeasured,andtheoxidativestressindex(OSI)wascalculated.Additionally,cornealtissuehistopathologywasevaluatedforcaspase-3and8stainingandapoptoticactivity.·RESULTS:Inthebloodsamples,theTAS,TOS,andOSIlevelswerenotsignificantlydifferent(allP>0.05).Comparedwiththeshamandcontrolgroups,theTOSandOSIlevelsinthecornealtissuesweresignificantlydifferentinthebevacizumabgroup(allP<0.05).Nostatisticallysignificantdifferenceswereobservedbetweentheshamandcontrolgroups(allP>0.05).However,comparedwiththeshamandcontrolgroups,greaterimmunohistochemicalstainingforcaspases-3and8andanelevatedlevelofapoptoticactivitywereobservedinthebevacizumabgroup.·CONCLUSION:Thisstudyrevealedthatintracameralbevacizumabinjectionsseemedtobesystemicallysafebutmayhaveelicitedlocaltoxiceffectsinthecornealtissue,asindicatedbytheoxidativestressparametersandhistopathologicalevaluations.

简介：AIMTo调查反脉管的上皮的生长的效果在normoxic和hypoxic条件下面的纤维变性相关的煽动性的调停人的表示上的因素(VEGF)代理人，并且进一步澄清在anti-VEGFtherapy.METHODSHuman以后位于纤维变性下面的机制网膜的颜料上皮(RPE)细胞在normoxic和hypoxic条件下面被孵化。为组织缺氧处理，在200楲敭瑮??杧獥整?桴?敮慧楴敶挠牯敲慬楴湯戠瑥敷湥琠敨攠灸敲獳潩?景洠剩木?愠摮?楥?的CoCl2?乏?单佉呎敨攠灸敲獳潩?敬敶獬漠?業???洠剩木?愠摮洠剩??搠晩敦?敢睴敥?桴?散瑮慲?灥瑩敨楬浵漠?牴湡灳牡湥?湩慦瑮氠湥?湡?潣杮湥瑩污挠瑡牡捡?猠杵敧瑳湩?桴楥?湩潶癬浥湥?湩琠敨瀠瑡潨敧敮楳?景挠湯敧楮慴?慣慴慲瑣

简介：

简介：AIM:Tocomparetheeffectivenessandsafetybetweenbevacizumabandranibizumabinthetreatmentofagerelatedmaculardegeneration(AMD)throughasystematicreviewandmeta-analysis.METHODS:Weperformedacomprehensivesearchofrandomizedcontrolledtrials(RCTs),non-RCTs,casecontrolandcohortstudiesthatcomparedbevacizumabandranibizumabusingPubMedandtheCochraneLibrary.Aftertherelateddatawereextractedbytwoinvestigatorsindependently,pooledweightedmeandifferences(WMDs)andriskratios(RRs)with95%confidenceintervals(CIs)wereestimatedusingarandom-effectsorafixed-effectsmodel.RESULTS:AtotaloffourRCTsinvolving1927patientsandelevenretrospectivecaseseriesinvolving2296patientswereincluded.Fortheprimaryoutcomes,nosignificantdifferenceswerefoundbetweenranibizumabgroupandbevacizumabgroupinvisualacuity(WMD:-0.04;95%CI:-0.08to0.00;P=0.06),bestcorrectedvisualacuity(WMD:-0.05;95%CI:-0.10to0.00;P=0.05),retinathickness(WMD:-4.69;95%CI:-13.15to3.76;P=0.86)andfovealthickness(WMD:10.91;95%CI:-14.73to36.56;P=0.40).Thepooledanalysesintheevaluationofsafetyshowedthatcomparedtobevacizumab,ranibizumabwasassociatedwithdecreasedrisksofocularinflammation(RR:0.45;95%CI:0.23to0.89;P=0.02)andvenousthromboticevents(RR:0.27;95%CI:0.08to0.89;P=0.03).However,therewerenosignificantdifferencesobservedindeaths(P=0.69)andarterialthromboembolicevents(P=0.71)betweenthetwogroups.CONCLUSION:Withequalclinicalefficacy,ranibizumabwasfoundtobeassociatedwithlessadverseeventscomparedtobevacizumab,indicatingthatranibizumabmightbeasafermanagement.

简介：

简介：目的：探讨玻璃体腔注射贝伐单抗（bevacizumab）联合Ex-press青光眼引流管植入术治疗新生血管性青光眼的疗效和安全性。方法：对18例19眼新生血管性青光眼患者，先行玻璃体腔注射bevacizumab，待虹膜新生血管消退或萎缩后，再行Ex-press青光眼引流管（P-200）植入术，其中6例6眼联合超声乳化白内障吸除术。根据患者屈光介质情况术前或术后尽量行全视网膜光凝。Ex-press植入术后随访12mo，观察视力、眼压和手术并发症情况。结果：玻璃体腔注药后2～7d，16眼新生血管全部消退。术后平均眼压：1mo：13．05±2．46mmHg，3mo：13．80±1.88mmHg，6mo：14．30±1．38mmHg；12mo：14．60±1．43mmHg，术后1，3，6，12mo眼压与术前相比均有显著性差异（P＜0．05），且术后1，3，6，12mo眼压相比均无显著性差异（P＞0.05）。19眼术后视力有提高者4眼，无明显改变15眼，无视力下降眼，完全成功11眼（58％），部分成功5眼（26％），总手术成功率84％（16/19）。术后并发症：有2例术后早期短暂浅前房，散瞳1wk后前房恢复正常，1例前房少量积血，无排斥反应和严重并发症。结论：玻璃体腔注射bevacizumab可使新生血管青光眼虹膜新生血管迅速消退或萎缩，为下一步青光眼手术创造良好的条件。Ex-press青光眼引流管植入术是新的滤过性手术，该手术创伤小，不用切除虹膜，减少了术中、术后出血的风险，联合bevacizumab是治疗新生血管性青光眼的安全而有效的术式。

简介：Weevaluatedtheefficacyandsafetyofgammaknifestereotacticradiosurgery(GKSR)followedbybevacizumabcombinedwithchemotherapyin11patientswithrecurrentglioblastomamultiformewhoexperiencedtumorprogressiondespiteaggressiveinitial

简介：Bevacizumabisoneoftheraredrugsthatcouldimprovehigh-gradegliomaoutcomeafterfailureofchemoradiotherapy.However,todate,thereisnobiomarkerpredictiveforefficacyofbevacizumabtherapyintermsofsurvivalimprovementforpatientswithhigh-

简介：AIM:Toevaluatetheefficacyandsafetyofacombinedtreatmentformyopicchoroidalneovascularization(CNV)usingphotodynamictherapy(PDT)andintravitrealbevacizumabandtocompareitwithintravitrealbevacizumabmonotherapy.METHODS:Thirty-foureyeswithangiographicevidenceofmyopicCNVwererandomlydividedintotwogroups:17weretreatedwithoneintravitrealbevacizumabinjection(1.25mg)andlow-fluence-ratePDTwithinsevendaysoftheinjection(GroupA).Theother17receivedmonotherapywithbevacizumabinjections(GroupB).Clinicalevidenceofcomplications,bestcorrectedvisualacuity(BCVA)andfluoresceinleakagewereevaluated.BCVAandopticalcoherencetomography(OCT)wereevaluatedmonthly.Thetimepointsfollow-upwasestablishedat6and12mo.AllpatientswereretreatedfollowingaPRNprotocol.RESULTS:Atotalof34eyesof34patients(26womenand8men)withameanageof62.35yearswereincluded.InGroupA(17eyes)themeanBCVAincreasedfrom0.55±0.13logMARbeforethetreatmentto0.40±0.09logMARatthe12mofollow-up(P<0.01).InGroupB(17eyes)themeanBCVAincreasedfrom0.60±0.11logMARbeforethetreatmentto0.55±0.12logMARatthe12mofollow-up(P<0.01).TherewasnostatisticallysignificantdifferencebetweenthetwogroupsintermsofLogMarvisualacuity.InGroupAthemeannumberofcombinedtreatmentswas1.8±0.11perpatient;inGroupBthemeannumberofintravitrealbevacizumabinjectionswas3.1±0.08perpatient.ThenumberoftreatmentswassignificantlyfewerinGroupA(P<0.01).Nolocalorsystemicsideeffectsoccurredamonganyofthepatientstreatedinthisstudy.CONCLUSION:Thecombinationofanti-angiogenicinjectionsandPDTappearstobeasafeandeffectiveoptionformyopicCNVtreatmentandallowsforasignificantreductionofintravitrealinjections.

简介：AIM:Tocomparetheeffectsofintravitrealinjectionofbevacizumab(IVB)withintravitrealtriamcinoloneacetonide(IVTA)onthetreatmentofcystoidmacularedema(CME)secondarytoretinalveinocclusion(RVO).·METHODS:AliteraturesearchwasconductedusingPubMed,theCochraneCentralRegisterofControlledTrials,WebofScienceandtheChineseBiomedicalDatabase.Thecomparisonwasdividedintotwogroups,group1conductedcomparisoninbranchRVO(BRVO)orcentralRVO(CRVO),group2conductedcomparisoninischemic-RVOornonischemic-RVO.Pooledmeandifferences(MDs)forchangesinvisualacuity(VA),centralmacularthickness(CMT)andintraocularpressure(IOP)werecalculatedingroupsat4,12and24wkaftertreatmentrespectively.·RESULTS:EightstudiescomparingtheefficacyofIVBwithIVTAwereincludedintheMeta-analysis.Ingroup1,inBRVO,significantdifferencewasshownonthecomparisonofCMTat24wk(MD,-45.66;95%CI,-76.03to-15.28;P=0.003),IVBwaseffectiveonBRVOforatleast24wk;nosignificantdifferenceswerefoundinthecomparisonofVAateachtimepoints(P>0.05respectively).InCRVO,nosignificantdifferenceswerefoundinthecomparisonofVAorCMTbetweenIVBandIVTAateachtimepoints(P>0.05,respectively).Ingroup2,inischemic-RVO,significantdifferenceswereshowninthecomparisonofVA(MD,-0.28;95%CI,-0.42to-0.14;P<0.0001)andCMT(MD,-86.50;95%CI,-151.18to-22.43;P=0.008)at24wk;Innonischemic-RVO,nosignificantdifferencesweredemonstratedinthecomparisonofVAorCMTbetweenIVBandIVTAateachtimepoints(P>0.05,respectively).TheoccurrenceofhighIOPwasmuchlowerinIVBgroup.·CONCLUSION:ThisMeta-analysissuggestedthatIVBwaseffectiveindecreasingCMTinBRVOforatleast24wk,IVBismoreeffectiveonimprovingVAandreducingCMTinischemic-RVO.IVBismorepromisingonRVOthanIVTA.

简介：

简介：目的：研究当归芍药散配合小梁切除术联合bevacizumab治疗新生血管性青光眼的疗效。方法：将2011-01/2014-02期间我院收治的新生血管性青光眼患者纳入研究,根据治疗方法不同分为接受中西医药物配合小梁切除术治疗的观察组和接受西医药物配合小梁切除术治疗的对照组,比较两组患者的视力水平、眼压、视网膜神经纤维层厚度。结果：视力水平：治疗后1wk;6,12mo,观察组的患眼视力水平均明显高于对照组（0.41±0.07vs0.27±0.04,0.52±0.08vs0.38±0.06,0.72±0.14vs0.54±0.08）;眼压：治疗后1wk;6,12mo,观察组眼压明显低于对照组（15.11±3.22vs22.32±5.34,18.64±5.08vs26.67±6.22,17.18±3.76vs22.42±4.32）mmHg;视网膜神经纤维层厚度：治疗后12mo,观察组上方视野、下方视野、颞侧视野、鼻侧视野等神经纤维层厚度等神经纤维层厚度均明显高于对照组（90.41±10.52vs78.64±8.24,88.38±12.12vs72.37±8.82,73.21±8.46vs60.25±7.23,75.35±8.13vs62.63±7.29）μm。结论：当归芍药散配合小梁切除术联合bevacizumab治疗新生血管性青光眼有助于促进视力水平的恢复、控制眼压、改善视网膜神经纤维层厚度。

简介：AIMTo与有斑点的浮肿在病人在中央子字段foveal厚度(CSFT)上为intravitrealbevacizumab注射的短期的效果调查预兆的因素(我)对.METHODSThis是的中央网膜的静脉吸藏(CRVO)第二等在由于CRVO为我与intravitrealbevacizumab注射对待的60只眼睛的回顾的研究。后续是三个月。光谱域的光连贯断层摄影术(SD10月)测量的早治疗糖尿病的Retinopathy学习(ETDRS)分数和CSFT被用来在改正最好的视觉尖酸(BCVA)观察变化。基线BCVA，CSFT，年龄，CRVO持续时间和似胞的有斑点的浮肿(CME)或subretinal液体(SRF)的存在作为bevacizumabinjections.RESULTSBCVA在3mo在基线从0.9logMAR改进了到0.6logMAR的intravitreal的效果的潜在的预兆的因素被分析，它从721µ在CSFT与重要减小被联系；m到392µ；在注射以后的m3mo。大约50%CME盒子和超过90%SRF盒子在3mo与一个完全的决定对治疗作出回应。年龄(P=0.036)和低基线CSFT(P=0.037)与好3月的预后被联系。病人>；60岁在3mo完成了更好的CME分辨率(P=0.031)和更低的CSFT(305µ；m对474µ；m，P=0.003).CONCLUSIONIntravitrealbevacizumab显著地在3mo以后与CRVO在病人改进了视觉尖酸和CSFT。老年和更低的基线CSFT是短期的CSFT结果的好预言者。对bevacizumab的网膜的厚度反应可能取决于CME而非SRF的决定。

简介：AIM:Tocharacterizetemporalpatternofresolutionandrecurrenceofnaivechoroidalneovascularization(CNV)secondarytowetage-relatedmaculardegeneration(AMD)treatedwithintravitrealbevacizumabonasneededregimen,andtoanalyzebaselineriskfactorsforCNVresolutionorrecurrence.METHODS:Ninety-oneeyesof80patientswithnewlydiagnosedwetAMDwereretrospectivelystudied.Alleyesweretreatedwitharoundofthreemonthlyintravitrealbevacizumabinjections,followedbyoneadditional’bonus’injectionafterresolutionofCNVactivity.Duringfollow-up,eyesweremonitoredwithfluoresceinangiography,opticalcoherencetomography,andbest-correctedvisualacuity(BCVA).IncaseofrecurrencesofCNVactivity,eyeswereretreatedwithotherroundsofbevacizumabinjectionsfollowingthesametreatmentprotocol.RESULTS:Overamedianfollow-upof532d,themedianresolutiontimeofCNVactivityinthefirst,second,andthirdtreatmentroundwas98d,126d,and111d,respectively.Themedianrecurrencetimeforthethreeroundswas154d,126d,and151d,respectively.Nosignificantdifferenceinresolutiontime(P=0.09)orinrecurrencetime(P=0.11)wasdetectedamongtreatmentrounds.Age(P=0.0082)andlensstatus(P=0.035)werefoundtobeassociatedwithCNVresolution;forevery1-yearincreaseinagetherewas4%greaterchanceofCNVresolution;Phakiceyesdemonstrateda33%betterchancetoexperienceCNVresolutionthanpseudophakiceyes.ForCNVrecurrence,lensstatus(P=0.0009)andgender(P=0.0446)werefoundtobepredictive;pseudophakiceyeshada3.69-foldgreaterrisktoexperiencerecurrenceofCNVactivitycomparedtophakiceyes;maleshada2.19-foldgreaterrisktoexperiencerecurrenceofCNVactivitythanfemales.NosignificantBCVAchangesamongthreetreatmentroundswerenoted(P=0.56).CONCLUSION:ResolutiontimeandrecurrencetimeofCNVactivitywerenotsignificantlydifferentamongtreatmentrounds,suggestingabsenceoftachyphylaxistobevacizumab.Acautiousdecisionshouldbemadeupondisco